The therapeutic evaluation of radiofrequency ablation combined with S-1 capsules metronomic chemo-therapy for hepatocellular carcinoma
10.11904/j.issn.1002-3070.2016.01.004
- VernacularTitle:肝癌射频消融术后联合替吉奥节拍化疗的疗效评价
- Author:
Zhenguo KANG
;
Weizheng JI
;
Junpeng GU
;
Diwen ZHU
;
Haixiao ZHANG
;
Weixin REN
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
Radiofrequency ablation;
S-1;
Metronomic chemotherapy;
Thera-peutic evaluation
- From:
Practical Oncology Journal
2016;30(1):17-22
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficiency and safety of radiofrequency ablation combined with Tegafur,Gimeracil and Oteracil Porassium Capsules( S-1 capsules) for hepatocellular carcinoma.Methods Sixty HCC patients included in this study were underwent initial radiofrequency ablation and then they were di-vided into RFA+S-1 group and RFA control group according to the metronomic chemotherapy either with S-1 or not.The local tumor control and disease free survival outcome between the two groups were compared.Results Follow-up observation showed that the total control rate after 9 months′treatment was 93.3%in RFA+S-1 group vs.73.4%in RFA control group(P=0.038).During the 18 months of follow up,the median time for dis-ease free survival was 16.25 months in RFA+S-1 group vs.12.25 months in RFA control group( P<0.001) . One-year progression free survival rate in RFA group was 53.3%,which was significantly lower than the RFA+S-1 group(83.3%)(P=0.012).The major complication rate was 13.3%.No procedu rerelated death or severe complications occurred.Conclusion Metronomic chemotherapy with S-1 following initial radiofrequency ablation delays tumor progression and prolongs overall survival of patients with HCC tumors.
